Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK3S9J)

Drug Name
GSK1144814 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alcohol dependence 6C40.2 Phase 1 [1]
Schizophrenia 6A20 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMK3S9J

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuromedin-K receptor (TACR3) TTBPGLU NK3R_HUMAN Modulator [3]
Substance-P receptor (TACR1) TTZPO1L NK1R_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Substance-P receptor (TACR1) DTT TACR1 3.597 4.186 4.271 5.113
Neuromedin-K receptor (TACR3) DTT TACR3 3.406 4.248 2.982 1.138
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Schizophrenia [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Substance-P receptor (TACR1) DTT TACR1 7.40E-01 0.02 0.07
Substance-P receptor (TACR1) DTT TACR1 8.57E-01 -0.02 -0.18
Neuromedin-K receptor (TACR3) DTT TACR3 3.59E-01 0.04 0.12
Neuromedin-K receptor (TACR3) DTT TACR3 5.19E-01 -4.10E-03 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01181908) Alcohol Interaction Study. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01090440) Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (MNK112891) in GlaxoSmithKline.
3 Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.